Showing results (1-10 of 89) with videos related to
Sort By:
Pageof 9
Journal of Biopharmaceutical Statistics|May 25, 2010
Residuals and outliers in replicate design crossover studiesRobert Schall, Laszlo Endrenyi, Arne RingJournal of Biopharmaceutical Statistics|April 2, 2010
Statistical characterization of QT prolongationRobert Schall, Arne RingPharmaceutical Statistics|May 17, 2011
Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongationRobert Schall, Arne RingBritish Journal of Clinical Pharmacology|March 22, 2017
Statistical reporting of clinical pharmacology researchArne Ring, Robert Schall, Yoon K Loke, et al.International Journal of Clinical Pharmacology and Therapeutics|April 25, 2013
Approvable generic carbamazepine formulations may not be bioequivalent in target patient populationsLaszlo Tothfalusi, Laszlo EndrenyiJournal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|February 28, 2012
Sample sizes for designing bioequivalence studies for highly variable drugsLaszlo Tothfalusi, Laszlo EndrenyiPharmaceutical Research|April 3, 2003
Limits for the scaled average bioequivalence of highly variable drugs and drug productsLaszlo Tothfalusi, Laszlo EndrenyiOmics : a Journal of Integrative Biology|December 11, 2020
Rethinking Clinical Trials and Personalized Medicine with Placebogenomics and Placebo DoseVural Özdemir, Laszlo EndrenyiJournal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|May 12, 2010
Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products?Laszlo Endrenyi, Laszlo TothfalusiJournal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|January 8, 2014
Determination of bioequivalence for drugs with narrow therapeutic index: reduction of the regulatory burdenLaszlo Endrenyi, Laszlo TothfalusiPageof 9